Evidence map›Paper›PMID 32621804›Full record

ArticleAnalytical biochemistry2020

Ubiquitination of disease-causing CFTR variants in a microsome-based assay.

Samuel K Estabrooks, Jeffrey L Brodsky

Open access · greenAbstract read
In one paragraph

Article in Analytical biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Samuel K EstabrooksDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Jeffrey L BrodskyDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: jbrodsky@pitt.edu.
University of Pittsburgh · US

Funding

Modulating Hsp70-dependent proteostasis in Alzheimer's DiseaseR35GM131732 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JEFFREY L. BRODSKY · 2019 to 2026
$3.4M
NIGMS NIH HHS R35 GM131732
6 · The paper itself

Abstract

Soluble secreted proteins and membrane proteins are subjected to protein quality control pathways during their synthesis in the endoplasmic reticulum (ER) and delivery to other destinations. Foremost among these quality control pathways is the selection of misfolded proteins for ER-associated degradation (ERAD). A growing number of diseases, including Cystic Fibrosis, are linked to the ERAD pathway. In most cases, a membrane protein known as the Cystic Fibrosis Transmembrane Conductance Regulator, or CFTR, is prematurely degraded by ERAD. Cell-based assays and in vitro studies have elucidated factors required for the recognition and degradation of CFTR, yet mechanistic details on how these factors target specific disease-causing variants is limited. Given the possibility that variants might exhibit unique susceptibilities to ubiquitin modification, which is required for proteasome-mediated degradation, we devised an assay that recapitulates this event. Here, we demonstrate that ER-enriched membranes from transfected human cells support CFTR ubiquitination when combined with radiolabeled ubiquitin and isolated enzymes in the ubiquitination cascade. We also show that select disease-causing variants are ubiquitinated more extensively than wild-type channels and to varying degrees. Our system provides a platform to examine how other purified factors impact CFTR ubiquitination and the ubiquitination of additional disease-associated membrane proteins.

Indexed as

Biological AssayCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorEndoplasmic ReticulumHEK293 CellsHumansMicrosomesProteolysisUbiquitinationCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisERADF508del CFTRProtein quality controlUbiquitination

Identifiers

PMID32621804
PMCPMC7398851
OpenAlexW3039454834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.